Skip to main content
Tags: obesity | drug

Eli Lilly Exec: More Out of Pocket Payments for Obesity Drug

Eli Lilly Exec: More Out of Pocket Payments for Obesity Drug

Monday, 10 June 2024 08:57 PM EDT

 A top Eli Lilly (LLY.N) executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.

Patrik Jonsson, president of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said a mid-single digit percentage of patients paid the full list price out of pocket for Zepbound in the first quarter of 2024 in the U.S., which compares to the low single digits for Mounjaro.

© 2024 Thomson/Reuters. All rights reserved.


US
A top Eli Lilly (LLY.N) executive said on Monday that more patients are paying the full list price of its obesity drug Zepbound than those who had paid for its predecessor Mounjaro.Patrik Jonsson, president of Lilly Diabetes and Obesity, speaking at a Goldman Sachs...
obesity, drug
82
2024-57-10
Monday, 10 June 2024 08:57 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
Get the NewsmaxTV App for iOS Get the NewsmaxTV App for Android Scan QR code to get the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved